此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Amivantamab 和 Lazertinib 联合治疗与 Osimertinib 治疗局部晚期或转移性非小细胞肺癌的研究 (MARIPOSA)

2026年11月2日 更新者:Janssen Research & Development, LLC

Amivantamab 和 Lazertinib 联合治疗与 Osimertinib 和 Lazertinib 的 3 期随机研究作为 EGFR 突变的局部晚期或转移性非小细胞肺癌患者的一线治疗。

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).

研究概览

研究类型

介入性

注册 (实际的)

1074

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Beijing、中国、100853
        • Chinese PLA General Hospital
      • Beijing、中国、100050
        • Beijing Friendship Hospital Capital Medical University
      • Beijing、中国、100142
        • Beijing Cancer Hospital Respiratory Medicine Department II
      • Beijing、中国、100142
        • Beijing Cancer Hospital Respiratory Medicine Department I
      • Beijing、中国、101149
        • Beijing Chest hospital, Capital medical university
      • Changchun、中国、130000
        • Jilin cancer hospital
      • Changsha、中国、410013
        • Hunan Cancer hospital Thoracic Medicine Department II
      • Changsha、中国、410013
        • Hunan Cancer hospital Thoracic Medicine Department I
      • Changzhou、中国、213003
        • The First People's Hospital Of Changzhou
      • Chengdu、中国、610041
        • Sichuan Cancer Hospital
      • Chengdu、中国、610041
        • West China Hospital Sichuan University
      • Chongqing、中国、400038
        • Southwest Hospital
      • Guangzhou、中国、510080
        • The First Affiliated Hospital Sun Yat sen University
      • Guangzhou、中国、510120
        • Sun Yat-Sen Memorial Hospital Sun Yat-sen University
      • Hangzhou、中国、310022
        • Zhejiang Cancer Hospital
      • Hangzhou、中国、310009
        • Second Affiliated Hospital, School of Medicine, Zhejiang University
      • Hangzhou、中国、310009
        • The Second Affiliated Hospital of Zhejiang University College of Medicine
      • Hangzhou、中国、310016
        • Sir Run Run Shaw Hospital Zhejiang University School of Medicine
      • Harbin、中国、150000
        • Harbin medical university cancer hospital
      • Huizhou、中国、516001
        • Huizhou Municipal Central Hospital
      • Linhai、中国、317000
        • Taizhou Hospital of Zhejiang Province
      • Nantong、中国、226300
        • Nantong Tumor Hospital
      • Shanghai、中国、200030
        • Shanghai Chest Hospital
      • Shanghai、中国、200032
        • Fudan University Shanghai Cancer Center
      • Shanghai、中国、200123
        • Shanghai East Hospital
      • Shanghai、中国、200025
        • Ruijin Hospital Shanghai Jiao Tong University
      • Shenyang、中国、110004
        • Shengjing Hospital Of China Medical University
      • Tianjin、中国、300052
        • Tianjin Medical University General Hospital
      • Wenzhou、中国、325000
        • The First Affiliated Hospital of Wenzhou Medical University
      • Wuhan、中国、430030
        • TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
      • Xi'an、中国、710061
        • The First Affiliated Hospital of Xian Jiaotong University
      • Yantai、中国、264000
        • Yantai Yuhuangding Hospital
      • Zhengzhou、中国、450008
        • Henan Cancer Hospital
      • Ürümqi、中国、830000
        • Cancer Hospital of Xinjiang Medical University
      • Dnipro、乌克兰、49102
        • Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
      • Kharkiv、乌克兰、61070
        • Municipal non-profit enterprise 'Regional Center of Oncology'
      • Kyiv、乌克兰、02091
        • Medical Center 'Ok Clinic' of LLC 'International Institute of Clinical Studies'
      • Kyiv、乌克兰、03022
        • State Nonprofit Enterprise National Cancer Institute
      • Uzhhorod、乌克兰、88000
        • Municipal Oncology Centre of Uzhgorod Central Municipal Clinical Hospitlal
      • Haifa、以色列、3109601
        • Rambam Health Corporation
      • Jerusalem、以色列、9112001
        • Hadassah Medical Center
      • Kfar Saba、以色列、44281
        • Meir Medical Center
      • Petah Tikva、以色列、49100
        • Rabin Medical Center
      • Ramat Gan、以色列、5262100
        • Chaim Sheba Medical Center
      • Tel Aviv、以色列、6423906
        • Tel Aviv Sourasky Medical Center
      • Irkutsk、俄罗斯、664035
        • Irkutsk Regional Oncology Dispensary
      • Krasnoyarsk、俄罗斯、660133
        • Krasnoyarsk Regional Oncology Dispensary
      • Kuzmolovsky、俄罗斯、188663
        • Leningrad Regional Oncology Dispensary
      • Moscow、俄罗斯、115533
        • MCK
      • Moscow、俄罗斯、121205
        • Moscow City Oncology Hospital No 62
      • Nal'chik、俄罗斯、360000
        • City Clinical Hospital #1
      • Nizhny Novgorod、俄罗斯、603000
        • Nizhny Novgorod Regional Oncological Dispensary
      • Omsk、俄罗斯、664013
        • Omsk Clinical Oncology Dispensary
      • Saint Petersburg、俄罗斯、197758
        • N.N. Petrov Research Institute Of Oncology
      • Saint Petersburg、俄罗斯、196006
        • Oncology Medical Clinics AV Medical group
      • Saint Petersburg、俄罗斯、190121
        • Current medical technologies
      • Tambov、俄罗斯、392013
        • Tambov Regional Oncology Clinical Dispansary
      • Tomsk、俄罗斯、634050
        • Tomsk Cancer Research Institute
      • Ufa、俄罗斯、450083
        • Bashkir State Medical University
      • Yaroslavl、俄罗斯、150054
        • Yaroslavl Regional Clinical Oncology Hospital
    • Ontario
      • Brampton、Ontario、加拿大、L6R 3J7
        • William Osler Health System
      • Hamilton、Ontario、加拿大、L8V 5C2
        • Juravinski Cancer Centre
      • Ottawa、Ontario、加拿大、K1H 8L6
        • The Ottawa Hospital Cancer Centre
    • Quebec
      • Montreal、Quebec、加拿大、H4A 3J1
        • McGill University Health Centre
      • Budapest、匈牙利、H-1529
        • Orszagos Koranyi Tbc es Pulmonologiai Intezet
      • Farkasgyepü、匈牙利、8582
        • Veszprém Megyei Tudőgyógyintézet
      • Gyöngyös、匈牙利、3233
        • Mátrai Gyógyintézet-Bronchológia
      • Szombathely、匈牙利、9700
        • Markusovszky Egyetemi Oktatokorhaz
      • Székesfehérvár、匈牙利、8000
        • Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
      • Törökbálint、匈牙利、2045
        • Tudogyogyintezet Torokbalint
      • Hyderabad、印度、500034
        • Basavatarakam Indo-American Hospital
      • Kolkata、印度、700160
        • Tata Medical Center
      • Mumbai、印度、400012
        • Tata Memorial Hospital
      • Nashik、印度、422002
        • HCG Manavta Cancer Centre
      • Pune、印度、411013
        • Noble Hospital Pvt Ltd
      • Kaohsiung City、台湾、807
        • Kaohsiung Medical University Chung Ho Memorial Hospital
      • Kaohsiung City、台湾、833
        • Chang Gung Medical Foundation
      • Kaohsiung City、台湾、824
        • E-DA Hospital
      • New Taipei City、台湾、23561
        • Taipei Medical University Shuang Ho Hospital
      • Taichung、台湾、40447
        • China Medical University Hospital
      • Taichung、台湾、402
        • Chung Shan Medical University Hospital
      • Tainan、台湾、704
        • National Cheng Kung University Hospital
      • Taipei、台湾、10002
        • National Taiwan University Hospital
      • Adana、土耳其(türkiye)、01060
        • Adana City Hospital
      • Adana、土耳其(türkiye)、01250
        • Başkent University Medical Faculty Adana Application and Research Center
      • Ankara、土耳其(türkiye)、6800
        • Ankara Bilkent City Hospital
      • Ankara、土耳其(türkiye)、06560
        • Gazi Hastanesi
      • Edirne、土耳其(türkiye)、22030
        • Trakya University Medical Faculty
      • Istanbul、土耳其(türkiye)、34098
        • Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd
      • Istanbul、土耳其(türkiye)、34722
        • T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
      • Istanbul、土耳其(türkiye)、34214
        • Medipol Mega University Hospital
      • Izmir、土耳其(türkiye)、35575
        • Medical Point
      • Konya、土耳其(türkiye)、42080
        • Necmettin Erbakan University Meram Medical Faculty
      • Guadalajara、墨西哥、44280
        • Hospital Civil de Guadalajara Fray Antonio Alcalde
      • León、墨西哥、37000
        • CIMOVA, Morals Vargas Centro de Investigación SC
      • Mexico City、墨西哥、14050
        • Médica Sur
      • Mexico City、墨西哥、03100
        • Mexico Centre for Clinical Research, S.A. de C.V.
      • Monterrey、墨西哥、64710
        • i Can Oncology Center
      • México、墨西哥、14080
        • Instituto Nacional de Cancerologia
      • México、墨西哥、03100
        • Health Pharma Professional Research
      • Naucalpan、墨西哥、53100
        • Oncologia Integral Satelite
      • Barretos、巴西、14784-400
        • Fundacao Pio XII
      • Belo Horizonte、巴西、30110-022
        • Cetus Oncologia
      • Florianópolis、巴西、88020-210
        • Ynova Pesquisa Clinica
      • Ijuí、巴西、98700-000
        • Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda
      • Natal、巴西、59062 000
        • Liga Norte Riograndense Contra O Cancer
      • Pelotas、巴西、96020 080
        • UPCO Unidade de Pesquisa Clinica em Oncologia
      • Porto Alegre、巴西、90020-090
        • Irmandade Santa Casa de Misericordia de Porto Alegre
      • Porto Alegre、巴西、90610-000
        • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
      • Rio de Janeiro、巴西、22 250 905
        • Oncoclinicas Rio de Janeiro S A
      • Rio de Janeiro、巴西、20231 050
        • Ministerio da Saude Instituto Nacional do Cancer
      • Rio de Janeiro、巴西、22281 100
        • IDOR - Regional Rio de Janeiro
      • Sorocaba、巴西、18030-075
        • IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado
      • São Paulo、巴西、04014-002
        • Núcleo de Pesquisa São Camilo
      • São Paulo、巴西、01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo、巴西、01246 000
        • Fundacao Faculdade de Medicina Instituto do Cancer do Estado de Sao Paulo
      • Vitória、巴西、29308-014
        • Hospital Evangélico de Cachoeiro de Itapemirim
      • Bad Berka、德国、99437
        • Zentralklinik Bad Berka GmbH
      • Berlin、德国、14165
        • Helios Klinikum Emil von Behring GmbH
      • Cologne、德国、51109
        • Kliniken der Stadt Koeln gGmbH
      • Essen、德国、45147
        • Universitaetsklinikum Essen
      • Gauting、德国、82131
        • Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken Munchen-Gauting
      • Halle、德国、06120
        • Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
      • Heidelberg、德国、69126
        • Thoraxklinik am Universitatsklinikum Heidelberg
      • Heilbronn、德国、74072
        • Onkologische Schwerpunktpraxis
      • Leipzig、德国、04357
        • POIS Leipzig GbR
      • Oldenburg、德国、26121
        • Pius-Hospital Oldenburg
      • Stuttgart、德国、70376
        • Robert-Bosch-Krankenhaus - Klinik Schillerhoehe
      • Avellino、意大利、83100
        • Ospedale San Giuseppe Moscati di Avellino
      • Catania、意大利、95123
        • Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico
      • Meldola、意大利、47014
        • Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
      • Milan、意大利、20141
        • Istituto Europeo di Oncologia
      • Milan、意大利、20132
        • IRCCS Ospedale San Raffaele
      • Milan、意大利、20133
        • Fondazione IRCCS Istituto Nazionale dei Tumori
      • Milan、意大利、20122
        • Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
      • Monza、意大利、20052
        • San Gerardo Hospital
      • Naples、意大利、80100
        • Ospedale Monaldi
      • Orbassano、意大利、10043
        • Aou San Luigi Gonzaga
      • Ravenna、意大利、48121
        • Ospedale S. Maria Delle Croci
      • Roma、意大利、00168
        • Irccs Gemelli
      • Rozzano、意大利、20089
        • Istituto Clinico Humanitas
      • Bunkyō City、日本、113 8431
        • Juntendo University Hospital
      • Chūōku、日本、104 0045
        • National Cancer Center Hospital
      • Fukuoka、日本、810-8563
        • National Hospital Organization Kyushu Medical Center
      • Himeji、日本、670-8520
        • National Hospital Organization Himeji Medical Center
      • Hirakata、日本、573 1191
        • Kansai Medical University Hospital
      • Kanazawa、日本、920 8641
        • Kanazawa University Hospital
      • Kashiwa、日本、277 8577
        • National Cancer Center Hospital East
      • Kurume、日本、830-0011
        • Kurume University Hospital
      • Matsusaka、日本、515-8544
        • Matsusaka Municipal Hospital
      • Niigata、日本、951-8566
        • Niigata Cancer Center Hospital
      • Okayama、日本、700 8558
        • Okayama University Hospital
      • Osaka Sayama Shi、日本、589 8511
        • Kindai University Hospital
      • Shibukawa、日本、377-0280
        • National Hospital Organization Shibukawa Medical Center
      • Tokyo、日本、135 8550
        • The Cancer Institute Hospital of JFCR
      • Tokyo、日本、152 8902
        • National Hospital Organization Tokyo Medical Center
      • Toon-shi、日本、791-0295
        • Ehime University Hospital
      • Toyonaka-shi、日本、560-8552
        • National Hospital Organization Osaka Toneyama Medical Center
      • Wakayama、日本、641 8510
        • Wakayama Medical University Hospital
      • Yamaguchi、日本、740-8510
        • National Hospital Organization Iwakuni Clinical Center
      • Yamaguchi、日本、755-0241
        • National Hospital Organization Yamaguchi Ube Medical Center
      • Brussels、比利时、1200
        • Cliniques Universitaires Saint Luc
      • Charleroi、比利时、6060
        • Grand Hopital De Charleroi Site Les Viviers
      • Leuven、比利时、3000
        • UZ Leuven
      • Ottignies、比利时、1340
        • Clinique Saint Pierre
      • Roeselare、比利时、8800
        • Algemeen Ziekenhuis Delta
      • Bordeaux、法国、33000
        • Institut Bergonie
      • Bron、法国、69500
        • Hospices Civils de Lyon HCL
      • La Tronche、法国、38700
        • CHU de Grenoble Hopital Albert Michallon
      • Lille、法国、59000
        • Institute Coeur Poumon
      • Limoges、法国、87000
        • CHU de Limoges
      • Marseille、法国、13915
        • Hopital Nord
      • Paris、法国、75005
        • Institut Curie
      • Paris、法国、75970
        • Hopital Tenon
      • Pessac、法国、33604
        • CHU Bordeaux
      • Sain-Herblain、法国、44800
        • CHU Nantes
      • Saint-Mandé、法国、94163
        • HIA Begin
      • Tours、法国、37000
        • CHU Bretonneau
      • Villejuif、法国、94805
        • Institut Gustave Roussy
      • Bydgoszcz、波兰、85 796
        • Centrum Onkologii im Prof F Lukaszczyka
      • Gdansk、波兰、80 214
        • Uniwersyteckie Centrum Kliniczne
      • Gdynia、波兰、81 519
        • Szpitale Pomorskie Sp z o o
      • Olsztyn、波兰、10-357
        • Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie
      • Poznan、波兰、60-693
        • Private Specialist Hospitals - MedPolonia
      • Warsaw、波兰、02-781
        • Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
      • Rio Piedras、波多黎各、00935
        • Pan American Center for Oncology Trials LLC
      • Bangkok、泰国、10700
        • Siriraj Hospital
      • Bangkok、泰国、10400
        • Phramongkutklao Hospital and Medical College
      • Chiang Mai、泰国、50200
        • Chiang Mai University
      • Songkhla、泰国、90110
        • Songklanagarind Hospital, Prince of Songkla University
      • Bedford Park、澳大利亚、5042
        • Flinders Medical Centre
      • Heidelberg、澳大利亚、3084
        • Austin Hospital
      • Malvern、澳大利亚、3144
        • Cabrini Medical Centre
      • Murdoch、澳大利亚、6150
        • St John of God Hospital Murdoch
      • Nedlands、澳大利亚、6009
        • Sir Charles Gairdner Hospital
      • Westmead、澳大利亚、2145
        • Westmead Hospital
      • Wollongong、澳大利亚、2500
        • Southern Medical Day Care Centre
      • Woolloongabba、澳大利亚、4102
        • Princess Alexandra Hospital
    • Arizona
      • Goodyear、Arizona、美国、85395
        • Arizona Oncology Associates, PC - HAL
      • Yuma、Arizona、美国、85364
        • Yuma Regional Medical Center
    • California
      • Long Beach、California、美国、90813
        • City of Hope Long Beach Elm
      • Orange、California、美国、92868
        • University of California Irvine
    • Colorado
      • Lone Tree、Colorado、美国、80124
        • Rocky Mountain Cancer Centers
    • Florida
      • Jacksonville、Florida、美国、32256
        • Cancer Specialists of North Florida
    • Georgia
      • Athens、Georgia、美国、30607
        • University Cancer And Blood Center LLC
    • Louisiana
      • Metairie、Louisiana、美国、70006
        • East Jefferson General Hospital
    • Maryland
      • Columbia、Maryland、美国、21044
        • Maryland Oncology Hematology, PA
    • Michigan
      • Detroit、Michigan、美国、48202
        • Henry Ford Hospital
    • Minnesota
      • Edina、Minnesota、美国、55435
        • Minnesota Oncology Hematology P A
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic
    • Missouri
      • St Louis、Missouri、美国、63110
        • Washington University School Of Medicine
    • New Jersey
      • East Brunswick、New Jersey、美国、08816
        • Astera Cancer Care
    • Oregon
      • Eugene、Oregon、美国、97401
        • Willamette Valley Cancer Institute and Research Center
    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15232
        • University of Pittsburgh Medical Center
    • Tennessee
      • Nashville、Tennessee、美国、37203
        • Sarah Cannon Research Institute
    • Texas
      • Austin、Texas、美国、78745
        • Texas Oncology P A
      • Houston、Texas、美国、77030
        • Oncology Consultants Texas
    • Virginia
      • Fairfax、Virginia、美国、22031
        • Virginia Cancer Specialists
      • Edinburgh、英国、EH4 2XU
        • Edinburgh Cancer Centre Western General
      • London、英国、NW1 2PG
        • UCL Cancer Institute
      • London、英国、SW3 6JJ
        • The Royal Marsden NHS Trust
      • London、英国、SW10 9NH
        • Chelsea And Westminster Hospital
      • Manchester、英国、M20 4BX
        • Christie NHS Foundation Trust
      • Nottingham、英国、NG5 1PB
        • Nottingham University Hospitals NHS Trust
      • Sutton、英国、SM2 5PT
        • The Royal Marsden NHS Trust 1
      • 's-Hertogenbosch、荷兰、5223 GZ
        • Jeroen Bosch Ziekenhuis
      • Arnhem、荷兰、6815 AD
        • Rijnstate Ziekenhuis
      • Harderwijk、荷兰、3844 DG
        • Ziekenhuis St Jansdal
      • Nijmegen、荷兰、6525AG
        • UMC Radboud
      • Lisbon、葡萄牙、1769-001
        • Uls Santa Maria - Hosp. Pulido Valente
      • Porto、葡萄牙、4200-072
        • Instituto Portugues de Oncologia
      • Porto、葡萄牙、4099-001
        • Uls Santo Antonio - Hosp. Santo Antonio
      • Porto、葡萄牙、4100 180
        • Hosp. Cuf Porto
      • A Coruña、西班牙、15006
        • Hosp Univ A Coruna
      • Badalona、西班牙、08916
        • Inst. Cat. D'Oncologia-Badalona
      • Barcelona、西班牙、08025
        • Hosp. de La Santa Creu I Sant Pau
      • Barcelona、西班牙、08028
        • Hosp. Univ. Quiron Dexeus
      • Barcelona、西班牙、08035
        • Hosp Univ Vall D Hebron
      • Burgos、西班牙、09003
        • Hosp. Univ. de Burgos
      • Girona、西班牙、17007
        • Institut Català D'Oncologia Girona
      • Madrid、西班牙、28041
        • Hosp. Univ. 12 de Octubre
      • Madrid、西班牙、28046
        • Hosp. Univ. La Paz
      • Madrid、西班牙、28007
        • Hosp. Gral. Univ. Gregorio Maranon
      • Majadahonda、西班牙、28222
        • Hosp. Univ. Pta. de Hierro Majadahonda
      • Málaga、西班牙、29011
        • Hosp Regional Univ de Malaga
      • Pamplona、西班牙、31008
        • Clinica Univ. de Navarra
      • Seville、西班牙、41013
        • Hosp. Virgen Del Rocio
      • Valencia、西班牙、46014
        • Hosp. Gral. Univ. Valencia
      • Zaragoza、西班牙、50009
        • Hosp. Clinico Univ. Lozano Blesa
      • Buenos Aires、阿根廷、C1428ANZ
        • Instituto Alexander Fleming
      • Buenos Aires、阿根廷、C1426AGE
        • Centro Oncológico Korben
      • Córdoba、阿根廷、X5016KEH
        • Hospital Privado Centro Medico de Cordoba
      • La Rioja、阿根廷、F5300COE
        • Centro Oncologico Riojano Integral (Cori)
      • Viedma、阿根廷、R8500ACE
        • Clínica Viedma
      • Busan、韩国、48108
        • Inje University Haeundae Paik Hospital
      • Cheongju-si、韩国、28644
        • Chungbuk National University Hospital
      • Seongnam-si、韩国、13620
        • Seoul National University Bundang Hospital
      • Seoul、韩国、05505
        • Asan Medical Center
      • Seoul、韩国、03722
        • Severance Hospital Yonsei University Health System
      • Seoul、韩国、06351
        • Samsung Medical Center
      • Seoul、韩国、03181
        • Kangbuk Samsung Hospital
      • Seoul、韩国、06591
        • The Catholic University of Korea Seoul St Mary s Hospital
      • Seoul、韩国、8308
        • Korea University Guro Hospital
      • George Town、马来西亚、10990
        • Hospital Pulau Pinang
      • Johor Bahru、马来西亚、81100
        • Hospital Sultan Ismail
      • Kuala Lumpur、马来西亚、50586
        • Hospital Kuala Lumpur
      • Kuala Lumpur、马来西亚、59100
        • University Malaya Medical Centre
      • Kuantan、马来西亚、25100
        • Hospital Tengku Ampuan Afzan
      • Petaling Jaya、马来西亚、46050
        • Beacon Hospital Sdn Bhd

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Participant must have newly diagnosed histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is treatment naive and not amenable to curative therapy including surgical resection or chemoradiation
  • The tumor harbors exon 19 deletions (Exon 19del) or Exon 21 L858R substitution, as detected by an food and drug administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United states [US]) or an accredited local laboratory (sites outside of the US) in accordance with site standard of care
  • Mandatory submission of unstained tissue from tumor (in a quantity sufficient to allow for central analysis of EGFR mutation status and blood (for circulating tumor deoxyribonucleic acid [ctDNA], digital droplet polymerase chain reaction [ddPCR], and pharmacogenomic analysis)
  • Any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) Grade 1 or baseline level
  • Participant must have at least 1 measurable lesion, according to response evaluation criteria in solid tumors (RECIST) v1.1 that has not been previously irradiated. Measurable lesions should not have been biopsied during screening, but if only 1 non-irradiated measurable lesion exists, it may undergo a diagnostic biopsy and be acceptable as a target lesion, provided the baseline tumor assessment scans are performed at least 14 days after the biopsy

Exclusion Criteria:

  • Participant has received any prior systemic treatment at any time for locally advanced Stage III or metastatic Stage IV disease (adjuvant or neoadjuvant therapy for Stage I or II disease is allowed, if administered more than 12 months prior to the development of locally advanced or metastatic disease)
  • Participant has an active or past medical history of leptomeningeal disease
  • Participant with untreated spinal cord compression. A participant that has been definitively treated with surgery or radiation and has a stable neurological status for at least 2 weeks prior to randomization is eligible provided they are off corticosteroid treatment or receiving low-dose corticosteroid treatment less than or equal to (<=) 10 milligrams per day (mg/day) prednisone or equivalent
  • Participant has an active or past medical history of interstitial lung disease (ILD)/pneumonitis, including drug-induced or radiation ILD/pneumonitis
  • Participant has known allergy, hypersensitivity, or intolerance to the excipients used in formulation of amivantamab, lazertinib, or osimertinib, or any contraindication to the use of osimertinib
  • Participant has symptomatic brain metastases. A participant with asymptomatic or previously treated and stable brain metastases may participate in this study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment Arm A (Open-label): Amivantamab and Lazertinib

Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than (<) 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (>=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80*3) orally once daily.

Participants will receive amivantamab intravenously.

其他名称:
  • JNJ-61186372

Participants will receive lazertinib tablets orally.

其他名称:
  • JNJ-73841937和YH-25448
有源比较器:Treatment Arm B (Double-blind): Osimertinib+Placebo Lazertinib

Participants will receive osimertinib 80 mg orally once daily plus matching placebo of lazertinib 240 mg (80*3) orally once daily.

Participants will receive osimertinib capsules orally.

Participants will receive matching placebo orally.

实验性的:Treatment Arm C (Double-blind): Lazertinib+Placebo Osimertinib

Participants will receive lazertinib 240 mg (80*3) orally once daily plus matching placebo of osimertinib 80 mg orally once daily.

Participants will receive lazertinib tablets orally.

其他名称:
  • JNJ-73841937和YH-25448

Participants will receive matching placebo orally.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR)
大体时间:From randomization to either disease progression or death whichever occurs first (up to 32.8 months)

PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) the absence of progression, whichever came first. Disease progression was defined using RECIST 1.1 as a 20 percent (%) increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 millimeters (mL). Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment.

From randomization to either disease progression or death whichever occurs first (up to 32.8 months)

次要结果测量

结果测量
措施说明
大体时间
Overall Survival (OS)
大体时间:Approximately 60 months (time from the date of randomization until the date of death due to any cause)

Overall Survival is defined as the time from the date of randomization to the date of participant's death due to any cause.

Approximately 60 months (time from the date of randomization until the date of death due to any cause)
Objective Response Rate (ORR)
大体时间:Approximately 32.8 months

ORR is defined as the percentage of participants who achieve either a complete response (CR) or partial response (PR) as defined by BICR using RECIST v1.1 criteria.

Approximately 32.8 months
Duration of Response (DOR)
大体时间:Approximately 32.8 months

DOR is defined as the time from the date of first documented response (CR or PR) until the date of documented progression or death, whichever comes first, only for participants who achieve CR or PR as determined by the investigator using RECIST v1.1 criteria.

Approximately 32.8 months
Progression-Free Survival After First Subsequent Therapy (PFS2)
大体时间:Approximately 60 months

The PFS2 is defined as the time from randomization until the date of second objective disease progression, after initiation of subsequent anticancer therapy, based on investigator assessment (after that used for PFS) or death, whichever comes first.

Approximately 60 months
Time to Symptomatic Progression (TTSP)
大体时间:Approximately 60 months

TTSP is defined as the time from randomization to documentation in the electronic case report form (eCRF) of any of the following (whichever occurs earlier): onset of new symptoms or symptom worsening that is considered by the investigator to be related to lung cancer and requires either a change in anticancer treatment and/or clinical intervention to manage symptoms.

Approximately 60 months
Intracranial PFS
大体时间:Approximately 60 months

Intracranial PFS is defined as the time from randomization until the date of objective intracranial disease progression or death, whichever comes first, based on BICR using RECIST v1.1.

Approximately 60 months
Incidence and Severity of Adverse Events (AEs)
大体时间:Approximately 60 months

Incidence and severity of treatment emergent adverse events (TEAEs) will be reported. Any adverse event occurring at or after the initial administration of study treatment through the day of last dose plus 30 days, or until the start of subsequent anticancer therapy (if earlier), is considered to be treatment emergent.

Approximately 60 months
Number of Participants With Clinical Laboratory Abnormalities
大体时间:Approximately 60 months

Number of participants with clinical laboratory abnormalities (serum chemistry, hematology, blood coagulation, and urine samples) will be reported.

Approximately 60 months
Number of Participants With Vital Signs Abnormalities
大体时间:Approximately 60 months

Number of participants with vital signs abnormalities (temperature, heart rate, respiratory rate, oxygen saturation, blood pressure) will be reported.

Approximately 60 months
Number of Participants With Physical Examination Abnormalities
大体时间:Approximately 60 months

Number of participants with physical examination abnormalities will be reported.

Approximately 60 months
Serum Concentration of Amivantamab
大体时间:Approximately 60 months

Serum samples will be analyzed to determine concentrations of Amivantamab.

Approximately 60 months
Plasma Concentration of Lazertinib
大体时间:Approximately 60 months

Plasma samples will be analyzed to determine concentrations of Lazertinib.

Approximately 60 months
Number of Participants With Anti-Amivantamab Antibodies
大体时间:Approximately 60 months

Number of participants with antibodies to amivantamab will be reported.

Approximately 60 months
Change From Baseline in Non-Small Cell Lung Cancer - Symptom Assessment Questionnaire (NCSLC-SAQ)
大体时间:Baseline up to approximately 60 months

The NSCLC-SAQ contains 7 items that assess cough, pain, dyspnea, fatigue, and poor appetite over a 7-day recall period. Each multi-item scale and individual item will be summarized using count and percent by visit.

Baseline up to approximately 60 months
Change From Baseline in European Organization of Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
大体时间:Baseline up to approximately 60 months

EORTC-QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies.

Baseline up to approximately 60 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年9月30日

初级完成 (实际的)

2023年8月11日

研究完成 (估计的)

2028年2月16日

研究注册日期

首次提交

2020年7月23日

首先提交符合 QC 标准的

2020年7月23日

首次发布 (实际的)

2020年7月27日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • CR108856
  • 2020-000743-31 (EudraCT编号)
  • 73841937NSC3003 (其他标识符:Janssen Research & Development, LLC)
  • 2023-506576-27-00 (注册表标识符:EUCT number)
  • 2023 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅